What Is PFE Fair Value?
Pfizer Inc. (PFE) fair value estimate using multiple valuation models, updated daily.
As of August 1, 2026, Pfizer Inc. (PFE) has a composite fair value estimate of $43.53 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $25.01, suggesting the stock is undervalued by 74.0%.
Data as of August 1, 2026 (today)
Composite Fair Value
Undervalued4 of 4 models$43.53
vs. current price of $25.01(+74.0%)
How Is PFE Fair Value Calculated?
Four independent models estimate what PFE is worth. Each uses different inputs and assumptions. The composite blends them by weight.
PFE Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$52.92
+111.6%Undervalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$41.89
+67.5%Undervalued
Inputs used
PFE Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$32.37
+29.4%Undervalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$29.45
+17.7%Undervalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $25.01 is 111.6% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $12.62B | $11.97B |
| Year 2 | $12.88B | $11.57B |
| Year 3 | $13.13B | $11.19B |
| Year 4 | $13.40B | $10.82B |
| Year 5 | $13.66B | $10.46B |
| Year 6 | $13.94B | $10.11B |
| Year 7 | $14.22B | $9.78B |
| Year 8 | $14.50B | $9.46B |
| Year 9 | $14.79B | $9.14B |
| Year 10 | $15.09B | $8.84B |
| Terminal Value | $517.30B | $303.15B |
What Are PFE's Key Financial Metrics?
Earnings & Growth
Current Price
$25.01
EPS (TTM)
$1.31
Forward P/E
8.8
Profit Margin
11.8%
Cash & Balance Sheet
Free Cash Flow
12.4B
EBITDA
25.5B
Book Value
$15.81
Total Debt
64.7B
What Do Analysts Say About PFE?
Low
$24.00
Average
$28.75
High
$35.46
Upside
+14.9%
PFE Fair Value FAQ
What is the fair value of PFE?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), PFE's estimated fair value is $43.53. The stock is currently trading at $25.01, which makes it undervalued by our analysis.
How is PFE's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is PFE overvalued or undervalued?
Based on our analysis, PFE is undervalued. The current price of $25.01 is 74.0% below our estimated fair value of $43.53.
What do Wall Street analysts say about PFE?
26 analysts cover Pfizer Inc. with a consensus rating of "Buy." The average price target is $28.75, ranging from $24.00 to $35.46. This implies 14.9% upside from the current price.